IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Cypress Wealth Services LLC

Cypress Wealth Services LLC grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,243 shares of the medical research company’s stock after purchasing an additional 57 shares during the quarter. Cypress Wealth Services LLC’s holdings in IQVIA were worth $244,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Capital Performance Advisors LLP acquired a new stake in IQVIA during the 3rd quarter worth $27,000. Park Place Capital Corp purchased a new position in shares of IQVIA during the third quarter worth about $28,000. Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA during the second quarter worth about $29,000. Avior Wealth Management LLC grew its stake in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the last quarter. Finally, Assetmark Inc. increased its position in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after buying an additional 196 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE IQV opened at $197.25 on Friday. The company’s fifty day moving average is $200.09 and its two-hundred day moving average is $221.19. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The firm has a market capitalization of $35.80 billion, a P/E ratio of 25.89, a PEG ratio of 2.09 and a beta of 1.48. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on IQV shares. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a report on Wednesday, December 11th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Robert W. Baird dropped their price objective on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. Leerink Partners reiterated an “outperform” rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, JPMorgan Chase & Co. reduced their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $255.82.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.